Phase i safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours

European Journal of Cancer

Volumn 47, Issue 9, 2011, Pages 1328-1335

  De Jonge, M J A ^a   Dumez, H ^b   Kitzen, J J E M ^a   Beuselinck, B ^b   Verweij, J ^a   Courtney, R ^c   Battista, A ^c   Brega, N ^c   Schoffski P ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c PFIZER INC   (United States)

Author keywords

Docetaxel; Pharmacokinetic; Phase I; Solid tumours; SU 014813

Indexed keywords

DOCETAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SU 014813; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; COLITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HAIR DISCOLORATION; HUMAN; HYPERTENSION; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MAXIMUM TOLERATED DOSE; MELANOMA; NEOPLASMS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RESEARCH DESIGN; SAFETY; TAXOIDS; TREATMENT OUTCOME;

EID: 79957542419     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.02.012     Document Type: Article

References (22)

1. N.W. Gale, and G.D. Yancopoulos Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins and ephrins in vascular development Genes Dev 13 1999 1055 1066 (Pubitemid 29233137)
2. J.M. Cherrington, L.M. Strawn, and L.K. Shawver New paradigms for the treatment of cancer; the role of anti-angiogenesis agents Adv Cancer Res 79 2000 1 38 [Review]
3. M.C. Heinrich, C.D. Blanke, B.J. Druker, and C.L. Corless Inhibition of KIT tyrosine kinase activity: a novel approach to the treatment of KIT-positive malignancies J Clin Oncol 20 2002 1692 1703 (Pubitemid 34260552)
4. A. Shimizu, K.P. O'Brien, and T. Sjoblom The dermatofibrosarcoma protuberans-associated collagen type I alpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB Cancer Res 59 1999 3719 3723 (Pubitemid 29381878)
5. S. Patyna, A.D. Laird, and D.B. Mendel SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity Mol Cancer Ther 5 2006 774 782
6. D.B. Mendel, A.D. Laird, and X. Xin In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 2003 327 337 (Pubitemid 36109749)
7. O. Potapova, A.D. Laird, and M.A. Nannini Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248 Mol Cancer Ther 5 2006 1280 1289 (Pubitemid 43881321)
8. A.M. O'farrell, J.M. Foran, and W. Fiedler An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients Clin Cancer Res 9 2003 5465 5476 (Pubitemid 37499464)
9. Fiedler WM, Giaccone G, Lasch P, et al. Phase I trial of SU14813 in patients with advanced solid malignancies. Ann Oncol. 2010 Jul 6. [Epub ahead of print].
10. G.C. Jayson, G.J. Parker, and S. Mullamitha Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume J Clin Oncol 23 2005 973 981 (Pubitemid 46202317)
11. K. Pietras, K. Rubin, and T. Sjöblom Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy Cancer Res 62 2002 5476 5484
12. A. Kłosowska-Wardega, Y. Hasumi, and M. Burmakin Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma PLoS One 4 2009 e8149
13. G. Vlahovic, A.M. Ponce, and Z. Rabbani Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts Br J Cancer 97 2007 735 740 (Pubitemid 47396288)
14. S. Chan, K. Friedrichs, and D. Noel Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer J Clin Oncol 17 1999 2341 2354 (Pubitemid 29368232)
15. B. Chevallier, P. Fumoleau, and P. Kerbat Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organisation for Research and Treatment of Cancer J Clin Oncol 13 1995 314 322
16. V. Harvey, H. Mouridsen, and V. Semiglazov Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer J Clin Oncol 24 2006 4963 5790
17. Robert F, Sandler A, Schiller JH, et al. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemother Pharmacol 2009 Dec 31. [Epub ahead of print].
18. Zurita AJ, Liu G, Hutson T, et al. Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC). J Clin Oncol 2009;27:15s (suppl; abstract 5166).
19. S. Aamdal, I. Wolff, and S. Kaplan Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group Eur J Cancer 30 1994 1061 1064
20. Verweij J, Catimel G, Sulkes A, et al. Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1995;31a:S1-4.
21. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
22. Bergh J, Greil R, Voytko N, et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast acnecr (ABC). J Clin Oncol 2010;28:18s (suppl, abstract LBA1010).